Substance Use Disorders (SUD)Neurological InjuryImmunology & InflammationDMT

The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells

This in vitro study investigated whether DMT acts neuroprotective against oxidative stress within cultured neurons and immune cells derived from human precursor cells. Results indicate that DMT robustly increases the survival of these cells in response to severe oxygen deprivation, through activation of the Sig-1 receptor, a key modulator of cellular oxidative stress. The authors postulate that DMT may be endogenously generated to mitigate oxidative stress occasioned by adverse brain injuries such as ischemic infarcts.

Authors

  • Jordi Riba
  • Attila Szabo
  • Ede Ottó Frecska

Published

Frontiers in Neuroscience
individual Study

Abstract

Introduction

N,N-dimethyltryptamine (DMT) is a potent endogenous hallucinogen present in the brain of humans and other mammals. Despite extensive research, its physiological role remains largely unknown. Recently, DMT has been found to activate the sigma-1 receptor (Sig-1R), an intracellular chaperone fulfilling an interface role between the endoplasmic reticulum (ER) and mitochondria. It ensures the correct transmission of ER stress into the nucleus resulting in the enhanced production of antistress and antioxidant proteins. Due to this function, the activation of Sig-1R can mitigate the outcome of hypoxia or oxidative stress.

Methods

In this paper, we aimed to test the hypothesis that DMT plays a neuroprotective role in the brain by activating the Sig-1R. We tested whether DMT can mitigate hypoxic stress in in vitro cultured human cortical neurons (derived from induced pluripotent stem cells, iPSCs), monocyte-derived macrophages (moMACs), and dendritic cells (moDCs).

Results

DMT robustly increases the survival of these cell types in severe hypoxia (0.5% O2) through the Sig-1R. Furthermore, this phenomenon is associated with the decreased expression and function of the alpha subunit of the hypoxia-inducible factor 1 (HIF-1) suggesting that DMT-mediated Sig-1R activation may alleviate hypoxia-induced cellular stress and increase survival in a HIF-1-independent manner.

Discussion

Our results reveal a novel and important role of DMT in human cellular physiology. We postulate that this compound may be endogenously generated in situations of stress, ameliorating the adverse effects of hypoxic/ischemic insult to the brain.

Available with Blossom Pro

Research Summary of 'The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells'

Introduction

Ahmad and colleagues situate their study within research on the sigma-1 receptor (Sig-1R), an endoplasmic reticulum (ER) chaperone located at mitochondria-associated ER membranes (MAM). Sig-1R has been implicated in regulating Ca2+ signalling, ATP synthesis, ER-to-nucleus stress signalling (via chaperoning proteins such as IRE1), and in modulating cell survival, differentiation and immune responses. Previous in vitro and in vivo work indicates that Sig-1R agonists can protect against hypoxia and ischemic injury, and Sig-1R is expressed across neural and immune tissues. N,N-dimethyltryptamine (DMT), an endogenous tryptamine and known Sig-1R agonist, has been detected in mammalian tissues and is proposed to be sequestered in vesicles and increased by stress, but its physiological role remains unclear. The study therefore tests the hypothesis that DMT confers cellular protection against hypoxic stress via Sig-1R activation. Using human induced pluripotent stem cell (iPSC)-derived cortical neurons and monocyte-derived macrophages and dendritic cells (moMACs and moDCs, considered microglia-like), the investigators examine whether DMT affects survival in severe hypoxia and whether these effects involve modulation of hypoxia-inducible factor 1 alpha (HIF-1α) and dependence on Sig-1R signalling. The work aims to clarify a potential endogenous neuroprotective role for DMT and the mechanistic involvement of Sig-1R in human primary cell models.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (7)

Papers cited by this study that are also in Blossom

Cited By (21)

Papers in Blossom that reference this study

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis

Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)

Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)

The potential of psychedelics for the treatment of Alzheimer's disease and related dementias

Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)

N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q)

Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)

Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate

Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders

Olson, D. E. · Journal of Neurochemistry (2021)

Show all 21 papers
From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

Nichols, C. D., Wiatr, K., Figiel, M. et al. · Journal of Neurochemistry (2021)

63 cited
The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Psychedelics as a Novel Approach to Treating Autoimmune Conditions

Thompson, C., Szabo, A. · Immunology Letters (2020)

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)

Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)

Cameron, L. P. · ACS Chemical Neuroscience (2018)

Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT

Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)

112 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

The Endogenous Hallucinogen and Trace Amine... — Research Summary & Context | Blossom